🇺🇸July 24, 2026·15h agoResearch

Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma

Publisher

5AM Ventures

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: 5AM Ventures
Region: USA
Scope: Research
Published: July 24, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on 5amventures.com

Leave the platform to read the original full article on the publisher site.

Source: 5AM Ventures

Scope: Research

Open original article

Related coverage

More related coverage

Erasmus University Rotterdam/2h ago

Data centres consume vast amounts of electricity, but are not necessarily the main cause of grid peaks

European Molecular Biology Laboratory (EMBL)/3h ago

EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

Tohoku University Hospital/5h ago

河北新報「気になる症状すっきり診断」に放射線診断科科長高瀬圭教授の記事が掲載されました

PubMed — Nephrology & renal therapeutics/5h ago

Comparing the outcomes of non-papillary versus papillary mini-percutaneous nephrolithotomy for treatment of multiple renal stones: a prospective randomized study.